Biomarkers in Early Cancer Drug Development: Limited Utility

被引：17

作者：

Glassman, R. H. ^{[1
,2
]}

Ratain, M. J. ^{[3
]}

机构：

[1] Cornell Univ, Div Hematol & Oncol, Weill Med Coll, New York, NY 10021 USA

[2] Merrill Lynch & Co Inc, Healthcare Investment Banking, New York, NY USA

[3] Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2009年 / 85卷 / 02期

关键词：

GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; LIMITATIONS; MUTATIONS; SIGNAL;

D O I：

10.1038/clpt.2008.231

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：134 / 135

页数：2

共 18 条

[1] In biomarkers we trust? [J].

Baker, M .

NATURE BIOTECHNOLOGY, 2005, 23 (03) :297-304

[2] Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology [J].

Carroll, Kevin J. .

PHARMACEUTICAL STATISTICS, 2007, 6 (04) :253-260

[3] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

[4] Trends in the use and role of biomarkers in phase I oncology trials [J].

Goulart, Bernardo H. L. ;

Clark, Jeffrey W. ;

Pien, Homer H. ;

Roberts, Thomas G. ;

Finkelstein, Stan N. ;

Chabner, Bruce A. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6719-6726

[5]

Goulart BHL, 2004, J CLIN ONCOL, V22, p522S

[6] Selecting patients for epidermal growth factor receptor inhibitor treatment:: A FISH story or a tale of mutations? [J].

Johnson, BE ;

Jänne, PAJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6813-6816

[7] Molecular oncodiagnostics: Where we are and where we need to go [J].

Liu, ET .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) :2052-2055

[8] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[9]

MATHIEU M, 2007, PAREXELS BIO PHARM R

[10] Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker [J].

Pepe, MS ;

Janes, H ;

Longton, G ;

Leisenring, W ;

Newcomb, P .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 159 (09) :882-890

← 1 2 →